<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Next-Generation Discovery Proteomics: The Power of Ion Mobility Mass Spectrometry with Data-Independent Acquisition

Next-generation discovery proteomics in preclinical and translational research is an exciting application of this proteomic approach. By leveraging advanced technologies, the ability to identify and quantify thousands of proteins in an unbiased manner can have a significant impact on the overall development of novel therapies.

In this blog post, we explore not only the value of using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in discovery proteomics, but also the added value of incorporating ion mobility spectrometry (IMS) and data-independent acquisition (DIA) strategies.

The Power of LC-MS/MS and Proteomics in Preclinical Development

Shotgun proteomics is the practice of detecting proteins in complicated mixtures by employing bottom-up proteomics methods. In this approach, proteins are digested into peptides through enzymatic cleavage and then separated in LC prior to MS analysis.

There are typically three dimensions in a bottom-up proteomics by LC-MS/MS. Retention time (RT) is one dimension, and this translates to the amount of time it takes a solute to move through the column after it has been injected. The second dimension is the mass to charge ratio of the peptide, while the third is the intensity of the spectrum peaks.

LC-MS/MS is making significant contributions to both preclinical and clinical research (see here and here for examples). Specifically, it is being used in large-scale discovery proteomics for identifying and quantifying proteins—including post-translational modifications—that are differentially expressed across biological samples. For instance, it is being used for:

  • Global proteomics profiling of cells, biological fluids or tissues (+/- treatment)
  • Biomarker discovery and validation
  • Drug mechanism of action and toxicity studies
  • Disease mechanism studies
  • Target identification and validation

This large-scale approach generates highly robust and unbiased datasets that capture differences across all proteins simultaneously, as opposed to conventional techniques that focus on the detection and quantitative measurement of single proteins by using ligand-binding assays. It is important to note that effective use of this technique requires a multi-disciplinary team with expertise in analytical chemistry, biochemistry, and computational biology.

What Ion Mobility Spectrometry Adds to LC-MS/MS

Ion mobility spectrometry (IMS) is an analytical technique used to separate and identify ionized molecules in the gas phase based on their mobility in a carrier buffer gas. IMS integrates seamlessly with a typical LC-MS/MS process for IM-MS, effectively adding a fourth dimension of separation.

The figure below illustrates the four dimensions of separation when using IM-MS.

This additional dimension significantly enhances scanning speed, detection sensitivity, and proteomic analysis performance in terms of identification depth, detection cycle, and quantitative accuracy. This is a great benefit when analyzing complex samples and identifying low-abundance proteins.

Moreover, IM-MS allows for DIA, which means that the MS divides precursor ions into pre-defined isolation windows and then fragments them, followed by analysis of the fragments in each window by MS. Combining IMS and DIA strategies into LC-MS/MS is becoming increasingly common since doing so further improves sensitivity, detection depth, accuracy, and data reliability.

Overall, using IM-MS provides five major benefits:

  • Reduction in sample complexity and background noise since co-eluted species are separated.

  • Peak capacity is maximized by separating structural isomers, isobaric species, and species with differing charge states. Moreover, IM-MS can analyze both complex mixtures and single molecules since it combines broad analysis with precise targeting.

  • Seamless integration with other techniques (e.g., GC, LC) without disrupting the advantages of other processes in the workflow, such as chromatography and MS.

  • Information on an analyte’s structure via high precision collision cross section (CCS) values. The CCS measure enhances confidence when it comes to identifying molecules, reduces interference, and improves signal-to-noise ratios.

  • Developing insights into the structure and shape of molecules by comparing theoretical to experimental CCS values. This is important when it comes to developing insights into potential mechanisms of molecules of interest.

The Value of a DIA Strategy

DIA (Data Independent Acquisition) and DDA (Data Dependent Acquisition) are two common modes of MS data acquisition.

In DDA mode, the instrument selects which peptides to analyze based on the abundance of their precursor ions. The instrument will typically only analyze the most abundant ions in the sample and will skip over lower abundance ions. Not only DDA can miss low-abundance ions and over present high-abundance species, it also suffers from batch effect, where the results of experiments performed at different times or on different samples can be influenced by different levels of the most abundant species in each sample.

DIA, on the other hand, is a method of acquiring mass spectrometry data in which the instrument operates the same way for all peptides in the sample, regardless of their abundance. This results in the acquisition of mass spectra for all peptides, including low-abundance species, in the sample. Unbiased DIA strategies have gained popularity in the field of quantitative proteomics, because of its ability to provide comprehensive peptide coverage.

A graphical depiction of the key differences between DDA and DIA strategies is shown below.

Benefits of an IMS–Enhanced LC-MS/MS and DIA Strategy

Integrating the use of IMS and a DIA strategy in LC-MS/MS greatly improves sensitivity, detection depth, accuracy, and data reliability, and this approach is gaining popularity. As noted earlier, incorporating these elements into an LC-MS/MS workflow provides an additional dimension of separation and allows for deeper analysis of samples, with one study indicating that DIA identified between 2 and 3.3 times more proteins as compared to DDA, and another study reporting that more than 10,000 proteins were identified from a single cell type in 2 hours or less without prior MS measurements for spectral library generation.

Conclusion

Next generation IM-MS-based-proteomics in combination with a DIA strategy is enabling powerful proteomic analyses in preclinical and translational research for understanding the biological function of proteins, biomarker identification and validation, global proteomics profiling, and target identification and validation, among other uses.

Crown Bioscience offers next-generation ion mobility mass spectrometry (MS)-based proteomics services to global clients. Learn more about how we can help your next proteomics project.


Related Posts